Aktie A3EMJU BRIGHT MINDS BIOSCIENCES INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Bright Minds Biosciences Inc.

Aktien

A3EMJU

CA10919W4056

DRUG

Markt geschlossen - Canadian Securities Exchange
Andere Börsenplätze
 21:11:12 30.04.2024 		% 5 Tage % 1. Jan.
1.29 CAD -0.77% Intraday Chart für Bright Minds Biosciences Inc. -21.82% -39.15%
12.02. Bright Minds Biosciences Inc. meldet Ergebnis für das erste Quartal bis zum 31. Dezember 2023 CI
2023 Bright Minds Biosciences Inc. meldet Ergebnis für das am 30. September 2023 zu Ende gegangene Geschäftsjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Bright Minds Biosciences Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023
Bright Minds Biosciences Inc. Reports Earnings Results for the Full Year Ended September 30, 2023
Bright Minds Biosciences : Announces Closing of Non-Brokered Private Placement Fully Subscribed by Management - Form 6-K
Bright Minds Biosciences Inc. announced that it has received $0.9 million in funding
Bright Minds Announces Non-Brokered Private Placement Fully Subscribed by Management
Bright Minds Biosciences Inc. announced that it expects to receive $0.9 million in funding
Bright Minds Biosciences : Condensed Interim Consolidated Financial Statements For the three and nine months ended June 30, 2023 and 2022 (Expressed in Canadian Dollars) - Form 6-K
Bright Minds Biosciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023
Top Midday Gainers
Bright Minds Biosciences on "Positive" qEEG Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101
Bright Minds Biosciences Brief: Announcing "Positive" qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101
Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101
Bright Minds Biosciences Inc. Announces Positive qEEG (Quantitative Electroencephalogram) Data from Its First-In-Human Phase 1 Study of Lead Compound, Bmb-101
Bright Minds Biosciences : Announces Positive qEEG (Quantitative Electroencephalogram) Data fromits First-in-Human Phase 1 Study of Lead Compound, BMB-101
Bright Minds Biosciences Announced "Positive" Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101
Bright Minds Biosciences Inc. Announces Successful Completion of its Three-Part Phase 1 Study of BMB-101
Bright Minds Biosciences Brief: Announced "Positive" Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101
Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101
CSE Bulletin: Consolidation - Bright Minds Biosciences Inc. (DRUG)
Bright Minds Biosciences : Announces Proposed Share Consolidation
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3EMJU Aktie
  4. Nachrichten Bright Minds Biosciences Inc.
  5. Andere Sprachen